Vineet Pant1, Ishita B Sen, Arvinder S Soin. 1. Department of Nuclear Medicine, Fortis Memorial Research Institute, Medanta-The Medicity, Gurgaon, India. dr.vineet.pant@gmail.com
Abstract
OBJECTIVES: The aim of the study was to evaluate the role of F-fluorodeoxyglucose PET computed tomography (F-FDG PET CT) as an independent prognostic indicator in patients with hepatocellular carcinoma (HCC). MATERIALS AND METHODS: PET contrast-enhanced CT scans of 100 consecutive patients with HCC were reviewed retrospectively. Patients were asked to fast for 6 h before the study and blood glucose levels were monitored and ensured to be less than 200 mg/dl before injection of F-FDG. After administering the F-FDG injection (370-550 MBq) patients were instructed to rest comfortably for 45-60 min. All images were acquired using a dedicated GE Discovery PET/CT scanner. The PET CT scans of all the patients were reported separately by two nuclear medicine physicians. A stage-wise analysis of the compiled data was carried out. Lesions that showed standardized uptake values greater than background activity (activity in adjacent normal liver tissue) were defined as having increased F-FDG uptake. Pearson's χ -test or the Kruskal-Wallis test was used to assess statistical significance. A P value less than 0.05 was taken as significant. RESULTS: In this retrospective study of 100 HCC patients, a radiologically higher-stage disease was found more commonly in patients with F-FDG-avid primary tumors (P<0.001), whereas a lower-stage disease was found in patients with non-F-FDG-avid primary tumors. The non-F-FDG-avid tumors also showed lower incidence of metastatic disease and portal vein thrombosis (P<0.001). The histopathological findings of the patients who underwent liver transplantation demonstrated that a higher-grade tumor was more common in the F-FDG-avid tumor group than in the non-F-FDG-avid tumor group (P<0.05). CONCLUSION: An F-FDG PET CT scan can be used not only for staging but also as a tool for preoperative prediction of cellular differentiation in patients with HCC. The F-FDG uptake seen on a PET scan can serve as a molecular signature for management decisions and can be used as an independent and significant prognostic factor in patients with HCC.
OBJECTIVES: The aim of the study was to evaluate the role of F-fluorodeoxyglucose PET computed tomography (F-FDG PET CT) as an independent prognostic indicator in patients with hepatocellular carcinoma (HCC). MATERIALS AND METHODS: PET contrast-enhanced CT scans of 100 consecutive patients with HCC were reviewed retrospectively. Patients were asked to fast for 6 h before the study and blood glucose levels were monitored and ensured to be less than 200 mg/dl before injection of F-FDG. After administering the F-FDG injection (370-550 MBq) patients were instructed to rest comfortably for 45-60 min. All images were acquired using a dedicated GE Discovery PET/CT scanner. The PET CT scans of all the patients were reported separately by two nuclear medicine physicians. A stage-wise analysis of the compiled data was carried out. Lesions that showed standardized uptake values greater than background activity (activity in adjacent normal liver tissue) were defined as having increased F-FDG uptake. Pearson's χ -test or the Kruskal-Wallis test was used to assess statistical significance. A P value less than 0.05 was taken as significant. RESULTS: In this retrospective study of 100 HCC patients, a radiologically higher-stage disease was found more commonly in patients with F-FDG-avid primary tumors (P<0.001), whereas a lower-stage disease was found in patients with non-F-FDG-avid primary tumors. The non-F-FDG-avid tumors also showed lower incidence of metastatic disease and portal vein thrombosis (P<0.001). The histopathological findings of the patients who underwent liver transplantation demonstrated that a higher-grade tumor was more common in the F-FDG-avid tumor group than in the non-F-FDG-avid tumor group (P<0.05). CONCLUSION: An F-FDG PET CT scan can be used not only for staging but also as a tool for preoperative prediction of cellular differentiation in patients with HCC. The F-FDG uptake seen on a PET scan can serve as a molecular signature for management decisions and can be used as an independent and significant prognostic factor in patients with HCC.
Authors: Olivier Detry; Laurence Govaerts; Arnaud Deroover; Morgan Vandermeulen; Nicolas Meurisse; Serge Malenga; Noella Bletard; Charles Mbendi; Anne Lamproye; Pierre Honoré; Paul Meunier; Jean Delwaide; Roland Hustinx Journal: World J Gastroenterol Date: 2015-03-14 Impact factor: 5.742
Authors: Rania Refaat; Mohammad Abd Alkhalik Basha; Mohammed Sobhi Hassan; Rasha S Hussein; Ahmed A El Sammak; Dena Abd El Aziz El Sammak; Mohamed Hesham Saleh Radwan; Nahla M Awad; Somaia A Saad El-Din; Engi Elkholy; Dina R D Ibrahim; Shereen A Saleh; Iman F Montasser; Hany Said Journal: Eur Radiol Date: 2018-06-12 Impact factor: 5.315
Authors: Xifu Wang; Zhanliang Su; Tianchu Lyu; Matteo Figini; Daniel Procissi; Junjie Shangguan; Chong Sun; Bin Wang; Na Shang; Shanzhi Gu; Quanhong Ma; Andrew C Gordon; Kai Lin; Jian Wang; Robert J Lewandowski; Riad Salem; Vahid Yaghmai; Andrew C Larson; Zhuoli Zhang Journal: Radiology Date: 2017-12-12 Impact factor: 11.105
Authors: Liem H Nguyen; Daisy A Robinton; Marc T Seligson; Linwei Wu; Lin Li; Dinesh Rakheja; Sarah A Comerford; Saleh Ramezani; Xiankai Sun; Monisha S Parikh; Erin H Yang; John T Powers; Gen Shinoda; Samar P Shah; Robert E Hammer; George Q Daley; Hao Zhu Journal: Cancer Cell Date: 2014-08-11 Impact factor: 31.743